Results 121 to 130 of about 5,796 (217)

Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment. [PDF]

Infect Dis Ther
Polistena B, Midulla F, Sotgiu G, d'Angela D, Di Virgilio R, Spandonaro F.   +5 more
europepmc   +1 more source

Consenso formal basado en la evidencia y opinión de expertos en inmunoprofilaxis con palivizumab en pacientes con cardiopatía congénita [PDF]

openalex   +1 more source

iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering. [PDF]

MAbs
Kunze R, Navratil F, Beichert J, Geyer F, Floss DM, Kolmar H, Scheller J, Pudewell S.   +7 more
europepmc   +1 more source

Impact of Adopting 2014 Guidance for Palivizumab Prophylaxis for Children Previously Considered at High Risk for Severe Respiratory Syncytial Virus Disease [PDF]

, 2017
Rachel Quick
openalex   +1 more source

Virus-like Particle Vaccines Containing RSV Fusion Protein Cleavage Mutations Are Immunogenic and Protective in Cotton Rats With a Prime Dose. [PDF]

Immune Netw
Hwang HS, Kwon YM, Kim KH, Lee YT, Ko EJ, Meas A, Kang SM.   +6 more
europepmc   +1 more source

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants' First RSV Season in the UK. [PDF]

Infect Dis Ther
Chetty M, Costello P, Yarnoff B, Musci R, Ghemmouri M.   +4 more
europepmc   +1 more source

Implementation of a Palivizumab Order Panel to Decrease Inappropriate Use [PDF]

, 2019
Nada M. Rida, Alison C. Tribble, Kristin C. Klein   +2 more
openalex   +1 more source

RSV Prevention in Infants and Young Children. [PDF]

Am J Respir Crit Care Med
Cacho F, Sockrider M.
europepmc   +1 more source

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom. [PDF]

Int J Technol Assess Health Care
Hudson RDA, Rigoine de Fougerolles T, Leadley F, Chetty M, De La Tour P.   +4 more
europepmc   +1 more source

Informe técnico palivizumab inyectable

, 2016
En base a la revisión de la información científica respecto al medicamento Palivizumab 50mg inyectable, el Equipo Técnico acuerda no incluirlo en la Lista Complementaria de medicamentos al Petitorio Nacional Único de Medicamentos Esenciales (PNUME) debido a que no reduce la mortalidad y no es costo efectivo.
openaire   +1 more source